An Open Label, Multiple Dose Ranging Trial of AL721 in Patients With Persistent Generalized Lymphadenopathy and Symptomatic HIV Infection

Inclusion Criteria * Persistent generalized lymphadenopathy (PGL) (CDC-Group III), defined as palpable lymphadenopathy (nodes of 1 cm or greater) at two or more noncontiguous extrainguinal sites persisting for \> 3 months in the absence of an illness other than HIV infection to account for the findings. * AIDS related complex (ARC), defined as the presence of at least one of the following findings within 12 months prior to entry and the absence of a concurrent illness or condition other than HIV infection to explain the findings: * Any findings which define CDC-Group IV A. * History of any one of the findings that define CDC-Group IV C2. * Patients with any of the ARC symptoms can also have PGL and be enrolled in the protocol as ARC patients. * A positive antibody to HIV by any federally licensed ELISA test kit within 30 days of entry. Concurrent Medication: Allowed: * Topical or oral antifungal, antiviral, or antibiotic agents to treat oral candidiasis, herpes simplex, herpes zoster, or bacterial infections that develop during the course of the study. Exclusion Criteria * Exclude hemophiliacs. * Active substance abuse. * Alcohol consumption should be kept to a minimum. Co-existing Condition: Patients with the following will be excluded: * Hemophilia. * History or presence of an AIDS-defining opportunistic infection or malignancy. * AIDS related complex (ARC) patients with prior (within the last 12 months) or current history of diarrhea defined as = or \> 3 liquid stools per day persisting for longer than 1 month. * Significant malabsorption: * Greater than 10 percent weight loss within past 3 months with serum carotene \< 75 IU/ml or vitamin A \< 75 IU/ml. * Significant cardiac, liver, renal, or neurologic disorder. * Active ARC-defining secondary infection (oral candidiasis, oral hairy leukoplakia, multidermatomal herpes zoster, recurrent nontyphoidal Salmonella bacteremia or Nocardiosis) undergoing therapy or prophylaxis within 7 days of study entry. * Active tuberculosis under treatment. * Concurrent neoplasm other than basal cell carcinoma of the skin or in situ carcinoma of the cervix. Concurrent Medication: Excluded: * Any medication that will interfere with the assessment of AL-721, including nutritional supplements, vitamins, laxatives, and over-the-counter products containing lecithin. * Chemoprophylaxis for Pneumocystis carinii (PCP), candida, herpes simplex, herpes zoster infections, or bacterial infections. * Intravenous topical or oral antifungal, antiviral, or antibiotic agents to treat oral candidiasis, herpes simplex, herpes zoster, or bacterial infections that develop during the course of the study. * Systemic chemotherapy. Prior Medication: Excluded within 30 days of study entry: * Any investigational drug. * Biologic response modifiers. * Corticosteroids. * Chemotherapeutic agents. * Excluded within 90 days of study entry: * Any antiretroviral agent or AL-721.